Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

Recursion ended the year with $603 million in cash and equivalents and expects its cash runway to extend into 2027. This article was generated with the support of AI and reviewed by an editor. For ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...